AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02384720 — intervention group
Intervention type: OTHER
Intervention: Age: 41-64years
Study NCT02384720 — intervention group
Intervention type: OTHER
Intervention: Age: ≥65years
Study NCT06203808 — intervention group
Intervention type: OTHER
Intervention: COMPLETION OF QUESTIONNAIRES
Description: Both groups of patients will complete quality of life questionnaires at the time of treatment information, at 3 months, 6 months and at 12 months.
Study NCT05000320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuronal Injury Panel
Description: A panel of neuronal and astroglial assays that may be a marker of brain injury.
Study NCT05893290 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise Group
Description: Therapeutic exercise sessions will begin with a short educational talk that provides information on proper body mechanics, and the benefits of exercise, followed by simple warm-ups and three different stretching and five different strengthening exercises that emphasize hip, abdominal, and back muscles. The frequency of repetitions of each stretching and strength exercise will be 10 with a holding time of 10 sec. Each set of strengthening exercises will be followed by a different set of stretching exercises. Sessions will end with a short unguided period of deep slow breathing.
Study NCT05893290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise+Basic Body Awareness Therapy Group
Description: This group will receive BBAT as well as therapeutic exercises. Therapeutic exercises will include strengthening, stretching, and stabilization exercises. BBAT will include postural alignment, breathing, and cognitive exercises.
Study NCT06147154 — intervention group
Intervention type: OTHER
Intervention: 16S rRNA amplicon sequencing and untargeted metabolomics
Description: 16S rRNA sequencing is a method for large-scale identification of community composition, expression abundance, and phylogenetic analysis by polymerase chain reaction (PCR) amplification of specific variable regions of 16S rRNA, combined with high-throughput sequencing and bioinformatics analysis. It also enables large-scale identification of the entire flora in a given habitat to study microbial diversity.~Untargeted metabolomics refers to the use of Liquid Chromatograph Mass Spectrometer (LC-MS), Gas Chromatograph Mass Spectrometer (GC-MS), and nuclear magnetic resonance (NMR) technology. The dynamic changes of small molecular metabolites in cells, tissues, organs or organisms before and after stimulation or disturbance were detected without bias. The differential metabolites were screened by bioinformatics analysis, and the pathway analysis of differential metabolites was performed to reveal the physiological mechanism of their changes.
Study NCT06470724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structural visual approach
Description: The intervention comprised seven behavior approaches in this research defined as follows:~A successive approach: An approach to familiarization with the unfamiliar environment of the simulated dental office.~Tell-Feel-Show-Do (T-F-S-D): A dental approach explained to the patient's treatment by telling the patient what would happen, what he felt or did, and what had been done.~Visual pedagogy: Introduced dentistry to autistic children through visual media, such as pictures and photographs.~Audiovisual modeling: A learning process through audiovisual media, such as video and animation.~In-vivo modeling: Learning new activities by watching them in front of the model.~Behavioral trials: A learning strategy conducted through practicing the recent activity by him/herself.~Auto-modeling: A learning process following the activity of editing pictures during the prior visit of the patient.
Study NCT06096779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21-day cycle.
Study NCT06557122 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SOC and Advanced Bioengineered Skin Substitute
Description: SOC primary dressing with Helicoll®
Study NCT06557122 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SOC and Active Comparator
Description: SOC primary dressing with Epifix® or Grafix®
Study NCT05257993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JPI-547
Description: * Subjects are administered this investigational product once a week for 5 days, and have wash-out period for 2 days (5 Days on-2 Days off).~* The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).~* Capsules should be swallowed whole and should not be chewed, crushed or split.
Study NCT05257993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified FOLFIRINOX
Description: * After IV administration of Oxaliplatin 65 mg/m2 for 2 hours~* After IV administration of Leucovorin 400 mg/m2 for 2 hours + IV administration of Irinotecan 135 mg/m2 for 90 minutes (Irinotecan is started 30 minutes after the start of Leucovorin administration and administered simultaneously during the last 90 minutes of Leucovorin administration, but administered separately using a Y-connector without mixing)~* Continuous IV infusion of 5-FU 2400 mg/m2 for 46 hours~* Repeated administration every 2 weeks on a 14-day cycle
Study NCT05257993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-nab-paclitaxel
Description: * After IV administration of nab-paclitaxel 100 mg/m2 for 30 minutes~* IV administration of Gemcitabine 1000 mg/m2 for 30 minutes~* Administration on Days 1, 8, and 15 on a 28-day cycle
Study NCT05325645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712FUM/ Brexpiprazole fumarate
Description: 2 brexpiprazole QW tablets 24 mg (48 mg/dose) will be orally administered once weekly for 7weeks.(As an initial dose, one brexpiprazole QW tablet 24 mg and one placebo tablet will be orally administered (24 mg/dose))
Study NCT05325645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets will be orally administered once weekly for 7weeks.
Study NCT06193057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total ankle arthroplasty
Description: Patients who underwent ankle prosthesis implantation procedure with an anterior approach were involved in a longitudinal skin incision of about 12-15cm anterior to the tibio-tarsal joint in supine position. Once the deep layers were reached, passing through the anterior tibial tendon and extensor hallucis longus tendon sheath, the tibio-tarsal joint was then exposed. The operator proceeds to astragalic and tibial resections, once the appropriate size of implants was selected, the final components were implanted. In both groups, the basic prosthetic design approach will be 'three-component,' that is, with congruent mobile meniscus interposed between the tibial and astragalic components. At the end of the procedure, orthopedic walker boot was placed for 3 weeks, and progressive weight allowed.
Study NCT06193057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total ankle arthroplasty
Description: Patients who underwent ankle prosthesis implantation procedure with an anterior approach were involved in a longitudinal skin incision of about 12-15cm anterior to the tibio-tarsal joint in supine position. Once the deep layers were reached, passing through the anterior tibial tendon and extensor hallucis longus tendon sheath, the tibio-tarsal joint was then exposed. The operator proceeds to astragalic and tibial resections, once the appropriate size of implants was selected, the final components were implanted. In both groups, the basic prosthetic design approach will be 'three-component,' that is, with congruent mobile meniscus interposed between the tibial and astragalic components. At the end of the procedure, orthopedic walker boot was placed for 3 weeks, and progressive weight allowed.
Study NCT05936346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salvia haenkei 175mg
Description: The product appears as a soft gel containing the dry extract of Salvia haenkei
Study NCT05936346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salvia haenkei 350mg
Description: The product appears as a soft gel containing the dry extract of Salvia haenkei
Study NCT05727930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity, task-specific (i.e., walking) interventions
Description: Up to 30 1-hr sessions of training focused on walking trying to achieve higher cardiovascular intensities
Study NCT05727930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity, non-specific physical therapy interventions
Description: Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve higher cardiovascular intensities
Study NCT05727930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity, task-specific physical therapy interventions
Description: Up to 30 1-hr sessions of training focused on walking trying to achieve lower cardiovascular intensities
Study NCT05727930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity, non-specific physical therapy interventions
Description: Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve lower cardiovascular intensities
Study NCT05655156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPure XT
Description: Indication: reconstruction of knee ligaments to restore knee function and stability~The following device sizes are available for use in this indication:~* Size 5~  - Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 6~  - Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 8~  * Primary ACL reconstruction where autograft tissue is not suitable~ * Revision ACL reconstruction~ * Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 10~  * Multi-ligament reconstruction (recommended for posterior cruciate ligament (PCL) reconstruction)
Study NCT05853835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPX-TI641
Description: LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).
Study NCT05433584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT05433584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihyperglycemic medication
Description: As prescribed
Study NCT04340180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) gadolinium Breast MRI
Description: Standard of Care (SOC) gadolinium Breast MRI
Study NCT04340180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
Description: reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
Study NCT05978804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: Computerized Cognitive training (BrainHQ or Constant Therapy)
Study NCT05978804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS (tDCS) on DLPFC
Description: Device: Active tDCS on DLPFC Stimulation will be delivered by a constant current stimulator (Mind STIM). The electrical current will be administered to a pre-specified region of the brain (DLPFC). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
Study NCT06394830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNX001
Description: Intravesical administration of VNX001
Study NCT06064097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT06064097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection
Study NCT06064097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest x-ray
Study NCT06064097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT06064097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06064097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06064097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06064097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV
Study NCT06064097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT05467111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Exercise
Description: Patients will perform an acute bout of exercise (different types of exercise for each cycle of anthracyclines, as aerobic exercise, strength training or combined training) 24-48 hours prior to each cycle of anthracyclines.
Study NCT06064097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06237374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Vaccine Education Training & Patient-facing Chatbot Tool
Description: The first part of the intervention is a digital training provided to CHWs, which includes videos and job aids on vaccine education to support patient communication. The second part of the intervention is a patient-facing chatbot designed to provide key information about routine immunization that CHWs can share with their patients through the social media and messenger application, WhatsApp.
Study NCT06237374 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Training
Description: All CHWs in the study will receive the standard CHW training that is provided on an ongoing basis by Lwala Community Health Alliance.
Study NCT06064097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT06064097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT06064097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT06064097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06064097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06064097 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Receive radiation therapy
Study NCT06064097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo dental x-ray
Study NCT05560763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowTriever2 Catheter
Description: The FlowTriever2 Catheter is utilized for the treatment of Pulmonary Embolism
Study NCT06339008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3650150
Description: Administered SC
Study NCT06339008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT06339008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy for INCS
Description: Administered as intranasal spray
Study NCT06339008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy for INCS
Description: Administered as intranasal spray
Study NCT04466488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice Architecture
Description: 1. Providers will receive general training on TPT benefits, indications, and contra-indications.~2. Providers will be provided with updated ART and TPT prescribing approach, including an ink stamp or pre-printed sticker for quick entry of the ART prescription along with TPT and cotrimoxazole.~3. The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed
Study NCT05614765 — intervention group
Intervention type: DRUG
Intervention: Statin+Ezetimibe compound
Description: Crezet Tablet, Litorvazet Tablet
Study NCT06546930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DREAM intervention
Description: Virtual Peer Groups (VPGs)~Participants will have multiple opportunities to attend a VPG on a specific topic during their 12-month participation period. The VPG topics will include the following:~* Diabetes technology - basics or advanced use (audience-dependent)~* Family relationships and diabetes~* Diabetes in real life - school, work, social gatherings, travel~* Wellbeing and support when living with diabetes~* Working with your diabetes care team - who to call for what~* Eating and activity - what's different with T1D?~In-Person Events will be held quarterly to facilitate participant interaction and community-building. These gatherings will feature ice-breaker activities, refreshments, and hands-on learning opportunities, including the chance to interact with specific diabetes devices and engage with healthcare professionals and representatives from diabetes technology companies.
Study NCT04892940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) technique
Description: The PICO G2 4k helmet from the Chinese manufacturer Pico which is an autonomous virtual reality helmet will be used.~The sessions proposed last 20 minutes with a child pain protocol. The teenager will be able to choose his universe (forest, beach, mountain, aquatic, space), the voice that accompanies him (man, woman, none), the sound environment of music therapy (6 to choose from).~Each patient in the experimental group benefits from a virtual reality program including two daily sessions during their stay in the continuing care unit from the first post-operative day until the third post-operative day. Each session is proposed by a nurse anesthetist from the pain team and trained in the proper use of the equipment.This virtual reality program will be added to the standard analgesic protocol for the experimental group.
Study NCT04892940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic protocol
Description: Patients randomized in the control group receive the usual analgesic protocol of the department postoperatively.
Study NCT04892940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesic protocol
Description: Patients randomized in the control group receive the usual analgesic protocol of the department postoperatively.
Study NCT06524947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent recombinant norovirus vaccine (Pichia pastoris)
Description: Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) at a 30-day interval.~Main ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoVGII.4-VP1 protein, recombinant ReNoV GII.17-VP1 protein, aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate
Study NCT06237374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Training
Description: All CHWs in the study will receive the standard CHW training that is provided on an ongoing basis by Lwala Community Health Alliance.
Study NCT06233123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Medisafe android application (https://www.medisafe.com).
Description: software for Android mobile phones that can remind the patient of his treatment on time
Study NCT05585307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavtavirine
Description: Administered orally
Study NCT05585307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Administered orally
Study NCT05585307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (Substudy 01)
Description: Antiretroviral therapy, administered orally~Non-NNRTIs, examples: ABC/DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)
Study NCT05585307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1720
Description: Administered orally
Study NCT05585307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (Substudy 02)
Description: Antiretroviral therapy, administered orally~Example INSTIs: DTG/ABC/3TC or DTG/3TC
Study NCT05611138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Participants will be instructed to dissolve the protein powder in liquids (such as water) or on their food (e.g., yoghurt, oat porridge). A subset of the participants (max. 15 per arm) for visits 2 and 6 will be invited to participate in a postprandial challenge, where they will receive the daily protein portion as breakfast.
Study NCT05952830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT group
Description: subjects in ESWT-group receiving one session shock wave therapy given 6,000 impulses at 0.06-0.07 mJ/mm2 (1.2-1.4 bar) at 18 Hz on biceps brachii (17). Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute